Schell et al. [30] reported that APC may play a prognostic role in CRC and stated that routine clinical assessment of APC mutations together with KRAS, TP53, and BRAF may be used to predict CRC outcome. The gene discussed is KRAS; the disease is colorectal carcinoma.